LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
US$ ०.९५
०.००%
(०.००) 1D
अक्टोबर ७, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Mkt. cap
२३.९१ करोड
Avg. vol.
१३.६९ लाख
Volume
१९०.००
52-wk high
US$ २.०९
52-wk low
US$ ०.८८
EPS
-US$ ०.१४
Beta
१.६०
Shares outstanding
२५.२९ करोड
No. of employees
७५
Mkt. cap
२३.९१ करोड
Avg. vol.
१३.६९ लाख
Volume
१९०.००
52-wk high
US$ २.०९
52-wk low
US$ ०.८८
EPS
-US$ ०.१४
Beta
१.६०
Shares outstanding
२५.२९ करोड
No. of employees
७५
News stories
From web sources and news partners
PR Newswire UK
·
९ मिनेट पहिले
Skydance Debuts on NYSE Following 'Historic' Media Merger: NYSE Content Update
The Manila Times
·
१४ मिनेट पहिले
Primech Holdings (Nasdaq: PMEC) Subsidiary Earns 2026 LowCarbonSG Gold Leader Recognition Following 17.5% Year-on-Year Reduction in Scope 1 and 2 Emissions
GlobeNewswire
·
३४ मिनेट पहिले
Nexalin Technology Regains Compliance with Nasdaq Minimum
Yahoo Finance
·
४० मिनेट पहिले
1 S&P 500 Stock to Consider Right Now and 2 That Underwhelm
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc